炎症性肠病抗体药物研究进展  

Research progress of antibody drugs for inflammatory bowel disease

作　　者：何春梅 罗孝鑫 石真利 熊珍 HE Chunmei;LUO Xiaoxin;SHI Zhenli;XIONG Zhen(Department of Gastroenterology,Southwest Hospital,Army Medical University,Chongqing 400038,China;Department of Pathophysiology,People's Hospital of Chongqing Ba’nan District,Chongqing 401320,China)

机构地区：[1]陆军军医大学第一附属医院(西南医院)消化内科全军消化病研究所,重庆400038 [2]重庆医科大学附属巴南医院(重庆市巴南区人民医院)药剂科,401320

出　　处：《免疫学杂志》2023年第5期447-453,共7页Immunological Journal

摘　　要：肠道作为一个重要的消化器官和免疫器官,其免疫功能紊乱是炎症性肠病(IBD)的重要病理特征。对IBD免疫病理的深入了解促进了其靶向治疗的发展,现已研发了针对不同靶点的抗体生物制剂,改变了IBD的治疗模式,本文将综述抗体生物制剂在IBD中的研究进展。Intestinal tract is an important digestive and immune organ,and its immune dysfunction is an important pathological feature of inflammatory bowel disease(IBD).Understanding of the immunopathology of IBD has promoted the development of targeted therapy for IBD.Now antibody biologics targeting different targets have been developed,which has changed the treatment mode of IBD.Here we will review the research progress of therapeutic antibody in IBD.

关 键 词：炎症性肠病 抗体 生物制剂 细胞因子 淋巴细胞归巢 

分 类 号：R392.5[医药卫生—免疫学]